Challenges and Pitfalls of Stroke Therapeutics Research.
- Author:
Keun Hwa JUNG
1
Author Information
1. Department of Neurology, Seoul National University College of Medicine, Seoul, Korea. jungkh@gmail.com
- Publication Type:Review
- Keywords:
Stroke;
Therapeutics;
Research;
Neuroprotectant
- MeSH:
Annexin A2;
Benzenesulfonates;
Cell Death;
Diffusion;
Hydrogen;
Light;
Multiple Trauma;
Neurons;
Neuroprotective Agents;
Propylene Glycols;
Reperfusion Injury;
Sphingosine;
Stroke;
Fingolimod Hydrochloride
- From:Korean Journal of Stroke
2011;13(1):11-15
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Ischemia-reperfusion injury is complicated with multiple injury pathways. If a particular agent is used to restore blood flow and prevent cell death, many damaged neurons may come back to life. However, for stroke victims, there are no effective curative therapeutic approaches available other than thrombolytic treatment. The efficacy of neuroprotective agents are limited by low diffusion, narrow time window, strict dose titration, and lack of confidence at the preclinical level. NXY-059 reflects the fundamental limitation of neuroprotectant. There are recent attempts to overcome these limitations, with use of annexin A2, fingolimod, hydrogen, nitrite, and more. By covering two components, this report reviews what we have recently learned. In addition, it sheds light on some of the newer issues in clinical application.
